Steensma DP - Search Results

1

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.

Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. Bejar R, et al. Among authors: steensma dp. J Clin Oncol. 2012 Sep 20;30(27):3376-82. doi: 10.1200/JCO.2011.40.7379. Epub 2012 Aug 6. J Clin Oncol. 2012. PMID: 22869879 Free PMC article.

2

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A. Steensma DP, et al. Blood. 2005 Aug 15;106(4):1207-9. doi: 10.1182/blood-2005-03-1183. Epub 2005 Apr 28. Blood. 2005. PMID: 15860661 Free PMC article.

3

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Steensma DP, et al. J Clin Oncol. 2009 Aug 10;27(23):3842-8. doi: 10.1200/JCO.2008.19.6550. Epub 2009 Jun 15. J Clin Oncol. 2009. PMID: 19528372 Free PMC article. Clinical Trial.

4

The changing classification of myelodysplastic syndromes: what's in a name?

Steensma DP. Steensma DP. Hematology Am Soc Hematol Educ Program. 2009:645-55. doi: 10.1182/asheducation-2009.1.645. Hematology Am Soc Hematol Educ Program. 2009. PMID: 20008250 Review.

5

Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.

Steensma DP, Stone RM. Steensma DP, et al. Hematol Oncol Clin North Am. 2010 Apr;24(2):389-406. doi: 10.1016/j.hoc.2010.02.012. Hematol Oncol Clin North Am. 2010. PMID: 20359633 Review.

6

The molecular pathogenesis of myelodysplastic syndromes.

Davids MS, Steensma DP. Davids MS, et al. Among authors: steensma dp. Cancer Biol Ther. 2010 Aug 15;10(4):309-19. doi: 10.4161/cbt.10.4.12612. Epub 2010 Aug 5. Cancer Biol Ther. 2010. PMID: 20592488 Free article. Review.

7

A cello for Michayla.

Steensma DP. Steensma DP. J Clin Oncol. 2010 Oct 1;28(28):4400-1. doi: 10.1200/JCO.2010.30.0681. Epub 2010 Jul 26. J Clin Oncol. 2010. PMID: 20660826 Free PMC article. No abstract available.

8

The role of iron chelation therapy for patients with myelodysplastic syndromes.

Steensma DP. Steensma DP. J Natl Compr Canc Netw. 2011 Jan;9(1):65-75. doi: 10.6004/jnccn.2011.0007. J Natl Compr Canc Netw. 2011. PMID: 21233245 Review.

9

Hematopoietic growth factors in myelodysplastic syndromes.

Steensma DP. Steensma DP. Semin Oncol. 2011 Oct;38(5):635-47. doi: 10.1053/j.seminoncol.2011.04.014. Semin Oncol. 2011. PMID: 21943670 Review.

10

SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.

Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, Steensma DP, Pardanani A, Hanson CA, Tefferi A. Patnaik MM, et al. Among authors: steensma dp. Blood. 2012 Jan 12;119(2):569-72. doi: 10.1182/blood-2011-09-377994. Epub 2011 Nov 17. Blood. 2012. PMID: 22096241 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

497 results

Search Page

Filters